1
|
Geerts M, Hoeijmakers JG, van Eijk-Hustings Y, Brandts L, Gorissen-Brouwers CM, Merkies IS, Joore MA, Faber CG. Cost of illness of patients with small fiber neuropathy in the Netherlands. Pain 2024; 165:153-163. [PMID: 37556388 PMCID: PMC10723644 DOI: 10.1097/j.pain.0000000000003008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2023] [Revised: 06/14/2023] [Accepted: 06/16/2023] [Indexed: 08/11/2023]
Abstract
ABSTRACT Neuropathic pain is associated with substantial healthcare costs. However, cost-of-illness studies of small fiber neuropathy (SFN) are scarce. Our aim was to estimate the healthcare, patient and family, and productivity costs of patients with SFN in the Netherlands from a healthcare and societal perspective. In addition, the association of costs with age, pain impact on daily life, anxiety, depression, and quality of life (Qol) were examined. Cost questionnaires were completed by 156 patients with confirmed SFN. The average annual total health care and societal cost (€, 2020) was calculated at patient, SFN adult population, and societal level. The average annual healthcare, patient and family, and productivity costs per patient with a Pain Impact Numerical Rating Scale of 0 to 3 (mild), 4 to 6 (moderate), and 7 to 10 (severe) were calculated by using the cost questionnaire data. Quality of life was determined by the EuroQol 5D utility scores. Anxiety and depression were assessed using the Hospital Anxiety and Depression Scale. Associations of all costs were analyzed using linear regression analyses. At the patient level, the average annual SFN healthcare and societal cost of SFN was €3614 (95% confidence interval [CI] €3171-€4072) and €17,871 (95% CI €14,395-€21,480). At the SFN population level, the average healthcare costs were €29.8 (CI €26.4-€34.2) million, and on a societal level, these were €147.7 (CI 120.5-176.3) million. Severe pain was associated with significant lower Qol and higher depression scores, higher healthcare, patient and family, and productivity costs ( P < 0.001).
Collapse
Affiliation(s)
- Margot Geerts
- Department of Neurology, Maastricht University Medical Center+, School of Mental Health and Neuroscience, Maastricht, the Netherlands
| | - Janneke G.J. Hoeijmakers
- Department of Neurology, Maastricht University Medical Center+, School of Mental Health and Neuroscience, Maastricht, the Netherlands
| | - Yvonne van Eijk-Hustings
- Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center+, CAPHRI Care and Public Health Research Institute, Maastricht, the Netherlands
| | - Lloyd Brandts
- Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center+, CAPHRI Care and Public Health Research Institute, Maastricht, the Netherlands
| | - Carla M.L. Gorissen-Brouwers
- Department of Neurology, Maastricht University Medical Center+, School of Mental Health and Neuroscience, Maastricht, the Netherlands
| | - Ingemar S.J. Merkies
- Department of Neurology, Maastricht University Medical Center+, School of Mental Health and Neuroscience, Maastricht, the Netherlands
- Department of Neurology, Curacao Medical Center, J. H. J. Hamelbergweg, Willemstad, Curacao
| | - Manuela A. Joore
- Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center+, CAPHRI Care and Public Health Research Institute, Maastricht, the Netherlands
| | - Catharina G. Faber
- Department of Neurology, Maastricht University Medical Center+, School of Mental Health and Neuroscience, Maastricht, the Netherlands
| |
Collapse
|
2
|
Kolacz M, Kosson D, Puchalska-Kowalczyk E, Mikaszewska-Sokolewicz M, Lisowska B, Malec-Milewska M. Analysis of Antidepressant, Benzodiazepine Anxiolytic, and Hypnotic Use When Treating Depression, Anxiety, and Aggression in Pain Clinic Patients Treated for Neuropathic Pain. Life (Basel) 2022; 12:life12030433. [PMID: 35330184 PMCID: PMC8955855 DOI: 10.3390/life12030433] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2022] [Revised: 02/23/2022] [Accepted: 03/11/2022] [Indexed: 11/16/2022] Open
Abstract
Depression, anxiety, and aggression accompany neuropathic pain. Effective treatment of these comorbidities enhances the outcomes of pain management. Therefore, the study was designed to analyze the relationship between the intensity of depression, anxiety, and aggression and the pharmacotherapy applied in the daily practice of treating neuropathic pain. The aim of the study was to evaluate the frequency of using antidepressants (ADs), benzodiazepine anxiolytics (BDAs), and hypnotics, and the influence of administering these on the intensity of depression, anxiety, and aggression in patients diagnosed with neuropathic pain. A multi-center survey was conducted among 421 patients. An evaluation of the severity of depression, anxiety, and aggression was made using the Hospital Anxiety and Depression Scale—Modified Version (HADS-M). Among the patients treated due to neuropathic pain, ADs are used much more often than BDAs and hypnotics. Depression was well controlled, while anxiety was identified as a possible uncontrolled therapeutic problem in these patients, despite the correlation between the frequency of AD and hypnotics usage and the severity of anxiety. We also found that women show a higher level of intensity in both anxiety and depression, but this does not influence the frequency of their being administered ADs, BDAs, and hypnotics.
Collapse
Affiliation(s)
- Marcin Kolacz
- Ist Department of Anaesthesiology and Intensive Care, Medical University of Warsaw, 02-005 Warsaw, Poland;
| | - Dariusz Kosson
- Department of Anaesthesiology and Intensive Care Education, Medical University of Warsaw, 02-007 Warsaw, Poland;
- Correspondence: ; Tel./Fax: +48-(22)502-17-79
| | - Ewa Puchalska-Kowalczyk
- Department of Anaesthesiology and Intensive Care Education, Medical University of Warsaw, 02-007 Warsaw, Poland;
| | | | - Barbara Lisowska
- Department Anesthesiology and Intensive Medical Care, National Geriatrics, Rheumatology and Rehabilitation Institute, 02-637 Warsaw, Poland;
| | - Malgorzata Malec-Milewska
- Department of Anaesthesiology and Intensive Care, Medical Centre of Postgraduate Education, 00-416 Warsaw, Poland;
| |
Collapse
|
3
|
Retrospective Study on Ganglionic and Nerve Block Series as Therapeutic Option for Chronic Pain Patients with Refractory Neuropathic Pain. Pain Res Manag 2020; 2020:6042941. [PMID: 32774567 PMCID: PMC7399767 DOI: 10.1155/2020/6042941] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2020] [Revised: 06/03/2020] [Accepted: 06/13/2020] [Indexed: 11/18/2022]
Abstract
Objective Current recommendations controversially discuss local infiltration techniques as specific treatment for refractory pain syndromes. Evidence of effectiveness remains inconclusive and local infiltration series are discussed as a therapeutic option in patients not responding to standard therapy. The aim of this study was to investigate the effectiveness of infiltration series with techniques such as sphenopalatine ganglion (SPG) block and ganglionic local opioid analgesia (GLOA) for the treatment of neuropathic pain in the head and neck area in a selected patient group. Methods In a retrospective clinical study, 4960 cases presenting to our university hospital outpatient pain clinic between 2009 and 2016 were screened. Altogether, 83 patients with neuropathic pain syndromes receiving local infiltration series were included. Numeric rating scale (NRS) scores before, during, and after infiltration series, comorbidity, and psychological assessment were evaluated. Results Maximum NRS before infiltration series was median 9 (IQR 8–10). During infiltration series, maximum NRS was reduced by mean 3.2 points (SD 3.3, p < 0.001) equaling a pain reduction of 41.0% (SD 40.4%). With infiltration series, mean pain reduction of at least 30% or 50% NRS was achieved in 54.2% or 44.6% of cases, respectively. In six percent of patients, increased pain intensity was noted. Initial improvement after the first infiltration was strongly associated with overall improvement throughout the series. Conclusion This study suggests a beneficial effect of local infiltration series as a treatment option for refractory neuropathic pain syndromes in the context of a multimodal approach. This effect is both significant and clinically relevant and therefore highlights the need for further randomized controlled trials.
Collapse
|
4
|
Differential Diagnosis of Chronic Neuropathic Orofacial Pain: Role of Clinical Neurophysiology. J Clin Neurophysiol 2020; 36:422-429. [PMID: 31688325 DOI: 10.1097/wnp.0000000000000583] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
Orofacial pain syndromes encompass several clinically defined and classified entities. The focus here is on the role of clinical neurophysiologic and psychophysical tests in the diagnosis, differential diagnosis, and pathophysiological mechanisms of definite trigeminal neuropathic pain and other chronic orofacial pain conditions (excluding headache and temporomandibular disorders). The International Classification of Headache Disorders 2018 classifies these facial pain disorders under the heading Painful cranial neuropathies and other facial pains. In addition to unambiguous painful posttraumatic or postherpetic trigeminal neuropathies, burning mouth syndrome, persistent idiopathic facial and dental pain, and trigeminal neuralgia have also been identified with neurophysiologic and quantitative sensory testing to involve the nervous system. Despite normal clinical examination, these all include clusters of patients with evidence for either peripheral or central nervous system pathology compatible with the subclinical end of a continuum of trigeminal neuropathic pain conditions. Useful tests in the diagnostic process include electroneuromyography with specific needle, neurography techniques for the inferior alveolar and infraorbital nerves, brain stem reflex recordings (blink reflex with stimulation of the supraorbital, infraorbital, mental, and lingual nerves; jaw jerk; masseter silent period), evoked potential recordings, and quantitative sensory testing. Habituation of the blink reflex and evoked potential responses to repeated stimuli evaluate top-down inhibition, and navigated transcranial magnetic stimulation allows the mapping of reorganization within the motor cortex in chronic neuropathic pain. With systematic use of neurophysiologic and quantitative sensory testing, many of the current ambiguities in the diagnosis, classification, and understanding of chronic orofacial syndromes can be clarified for clinical practice and future research.
Collapse
|
5
|
Lancaster RJ, Wren K, Hudson A, Leavitt K, Albala M, Tischaefer D. Intravenous Lidocaine for Chronic Neuropathic Pain A Systematic Review Addressing Nursing Care. Pain Manag Nurs 2019; 21:194-200. [PMID: 31375420 DOI: 10.1016/j.pmn.2019.06.008] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2019] [Revised: 04/04/2019] [Accepted: 06/14/2019] [Indexed: 11/15/2022]
Abstract
BACKGROUND The intravenous administration of lidocaine for patients with chronic neuropathic pain is well documented in the literature. However, little is known about the role of the nurse caring for patients receiving the infusion. AIM The purpose of this systematic review was to examine and describe common side effects associated with the intravenous administration of lidocaine to patients with chronic neuropathic pain and outline nursing care described in an effort to develop evidence-based protocols for care. METHOD A comprehensive search of databases was completed and yielded eleven (n = 11) articles and one care protocol for analysis. RESULTS Evidence was appraised and findings suggest intravenous lidocaine has a low risk of causing adverse events, however patients should be monitored closely. CONCLUSIONS Nursing care focuses on pain assessment, close observation and intervention if neurological changes occur.
Collapse
Affiliation(s)
| | | | - Amy Hudson
- Aurora Medical Center, Oshkosh, Wisconsin
| | | | | | | |
Collapse
|
6
|
Lu Y, Li J, Liu Y. Depression as a mediator of quality of life in patients with neuropathic pain: A cross-sectional study. J Adv Nurs 2019; 75:2719-2726. [PMID: 31225663 DOI: 10.1111/jan.14111] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2018] [Revised: 03/29/2019] [Accepted: 04/29/2019] [Indexed: 01/16/2023]
Abstract
AIMS To explore whether pain intensity has an indirect effect on quality of life through mediation of depression in patients with neuropathic pain (NeP). DESIGN An observational, questionnaire-based, cross-sectional study. METHODS A convenience sample of patients suffering from NeP were enrolled from June 2015 - May 2016. Three questionnaires were used to collect data of pain intensity, Quality of life and depression. Andrew Hayes' PROCESS macro modelling tool for the SPSS software, based on the mediation Bootstrap confidence interval method, was used to analyse the mediation effect. RESULTS Both pain intensity and depression correlated negatively with the quality of life of patients. The indirect effect of pain intensity on the quality of life through depression was negative. CONCLUSIONS Increased pain intensity and depression were associated with a decreased quality of life in patients suffering from NeP and pain intensity had an indirect effect on the quality of life of patients through depression. IMPACT A low quality of life and depression are commonly seen in patients with NeP. However, little is known about the relationship between pain, quality of life and depression. Both pain intensity and depression had some negative effect on quality of life in patients with NeP. Pain intensity had an indirect effect on quality of life through a mediation effect of depression in patients with NeP. When caring for patients with NeP, nurses should assess depression routinely and try to alleviate it.
Collapse
Affiliation(s)
- Yue Lu
- School of Nursing, Peking University, Beijing, P.R. China
| | - Jing Li
- National Pain Diagnosis Centre, China-Japan Friendship Hospital, Beijing, P.R. China
| | - Yu Liu
- China Medical University, Shenyang, P.R. China
| |
Collapse
|
7
|
The reciprocal associations between catastrophizing and pain outcomes in patients being treated for neuropathic pain: a cross-lagged panel analysis study. Pain 2017; 157:1946-1953. [PMID: 28146042 DOI: 10.1097/j.pain.0000000000000594] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Catastrophizing is recognized as a key psychosocial factor associated with pain-related negative outcomes in individuals with chronic pain. Longitudinal studies are needed to better understand the temporal relationship between these constructs. The aim of this study was to determine if changes in catastrophizing early in treatment predicted subsequent changes in pain intensity and interference later in treatment, or alternately, if early changes in pain intensity and interference predicted subsequent changes in catastrophizing. A total of 538 patients with neuropathic pain were recruited from 6 multidisciplinary pain clinics across Canada. Study participants were asked to complete measures of catastrophizing, pain intensity, and interference when first seen in the clinic and then again at 3- and 6-month follow-ups. Cross-lagged panel analyses were used to determine the temporal associations among the study variables. The results showed that decreases in catastrophizing early in treatment prospectively predicted improvement in both pain intensity and interference later in treatment. Converse temporal relationships were also found, where a reduction in pain intensity and interference early in treatment predicted a subsequent diminishing of catastrophizing. All 4 unique cross-lagged correlations significantly accounted for an additional 4% to 7% of the total variance. The findings are consistent with theoretical models hypothesizing a causal impact of catastrophizing on pain, suggesting a mutual causation between these factors. The results support that treatments targeting catastrophizing may influence other pain-related outcomes, and conversely that treatments aiming to reduce pain could potentially influence catastrophizing. There may therefore be multiple paths to positive outcomes.
Collapse
|